Plasma Based Biomarkers in Advanced Prostate Cancer - Gerhardt Attard

(Length of Presentation: 16 min)

Gerhardt Attard, MD focuses on DNA Plasma-based biomarkers in advanced prostate cancer during his 2017 APCCC presentation on the rationale for using plasma DNA. Plasma collection is routine and are adding to the registries allows for ongoing clinical trials.  Circulating tumor DNA is detected in plasma from all progressing mCRPC patients.  Plasma DNA is representative of clinically relevant progressing metastases. Plasma DNA could be used to select targeted treatment - however we now need prospective clinical trials to evaluate this approach prior to changing clinical management of mCRPC patients.  

Biography: Gerhardt Attard, MD, Ph.D., The Institute of Cancer Research and Royal Marsden NHS Foundation Trust

VIew all: Advanced Prostate Cancer Consensus Conference Coverage

Read the 2017 APCCC Report published in European Urology on Management of Patients with Advanced Prostate Cancer

A Presentation by Gerhardt Attard, Using Liquid Biopsies to Interrogate Circulating Tumor Clone Dynamics and Prostate - Session Highlights








E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe